|
Opevesostat Clinical Trials
5 actively recruiting trials across 5 locations
▲ +1 trial since July 2026
Also known as: MK-5684, ODM-208
Pipeline
Phase 2: 1Phase 3: 2Phase 1/2: 2
Top Sponsors
- Merck Sharp & Dohme LLC5
Indications
- Cancer5
- Castration-Resistant Prostatic Cancer1
- Prostatic Neoplasms, Castration-Resistant1
- Metastatic Castration-resistant Prostate Cancer, mCRPC1
- Metastasis1
Anchorage, Alaska1 trial
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Alaska Womens Cancer Care ( Site 0037)
Phase 2
Tucson, Arizona1 trial
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The University of Arizona Cancer Center - North Campus ( Site 0073)
Phase 3
La Jolla, California1 trial
Los Angeles, California1 trial
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
UCLA Hematology & Oncology ( Site 0003)
Phase 1/2
Orange, California1 trial
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.